All Open Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0116Investigator Mark Roschewski, M.D. -
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0112Investigator Christopher G. Kanakry, M.D. -
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0104Investigator William L. Dahut, M.D. -
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
Open - RecruitingNCI Protocol ID NCI-19-C-0103Investigator Mark Roschewski, M.D. -
A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple Myeloma
Open - RecruitingNCI Protocol ID NCI-19-C-0102Investigator James N. Kochenderfer, M.D. -
Studying the biology of IDH-mutant gliomas via longitudinal observation of 2-hydroxyglutarate (2-HG) using MR spectroscopy
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0096Investigator Jing Wu, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Ann McCoy 240-760-6021 Christine Bryla 240-760-6007 -
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0094Investigator Tim F. Greten, M.D. -
A Phase II Study of Immunotherapy with E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Open - RecruitingNCI Protocol ID NCI-19-C-0091Investigator Christian S. Hinrichs, M.D. -
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-19-C-0085Investigator Jennifer A. Kanakry, M.D. -
Natural History Study of Children and Adults with Chordoma
Open - RecruitingNCI Protocol ID NCI-19-C-0082Investigator Brigitte C. Widemann, M.D. -
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0077Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-17-C-0077Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0078Investigator Dickran G. Kazandjian, M.D. -
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Open - RecruitingNCI Protocol ID NCI-19-C-0076Investigator Milos Miljković, M.D., M.Sc. -
A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Open - RecruitingNCI Protocol ID NCI-19-C-0041Investigator Vassiliki Saloura, M.D. Ph. D. -
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0062Investigator William L. Dahut, M.D. -
A Phase 2 Trial of The MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0061Investigator Brigitte C. Widemann, M.D. -
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
Open - RecruitingNCI Protocol ID NCI-19-C-0046Investigator James N. Kochenderfer, M.D. -
Long term follow-up of mesothelioma patients and their family members with germline mutations in BAP1 and other genes
Open - RecruitingNCI Protocol ID NCI-19-C-0049Investigator Raffit Hassan, M.D. -
A Phase I study of Moxetumomab pasudotox (Lumoxiti™) and Rituximab (Rituxan®) for Relapsed Hairy Cell Leukemia
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0042Investigator Robert J. Kreitman, M.D.